



National
Comprehensive
Cancer
Network®

NCCN Clinical Practice Guidelines in Oncology™

Melanoma

V.1.2010

Continue

www.nccn.org

NCCN Melanoma Panel Members

* Daniel G. Coit, MD/Chair ¶
Memorial Sloan-Kettering Cancer Center

Robert Andtbacka, MD ¶
Huntsman Cancer Institute
at the University of Utah

Christopher K. Bichakjian, MD ⊖
University of Michigan
Comprehensive Cancer Center

William E. Carson, III, MD ¶
The Ohio State University
Comprehensive Cancer Center -
James Cancer Hospital and
Solove Research Institute

Raza A. Dilawari, MD ¶
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

Dominick DiMaio, MD ≠
UNMC Eppley Cancer Center
at The Nebraska Medical Center

Valerie Guild ¥
Aim at Melanoma

Allan C. Halpern, MD ⊖ ⊢
Memorial Sloan-Kettering Cancer Center

F. Stephen Hodi, Jr. MD †
Dana-Farber/Brigham and Women's
Cancer Center

Mohammed Kashani-Sabet, MD ⊖
UCSF Helen Diller Family
Comprehensive Cancer Center

Mark C. Kelley, MD ¶
Vanderbilt-Ingram Cancer Center

Julie R. Lange, MD, ScM ¶
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Anne Lind, MD ≠
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University
School of Medicine

Lainie Martin, MD †
Fox Chase Cancer Center

Mary C. Martini, MD ⊖
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Scott K. Pruitt, MD, PhD ¶
Duke Comprehensive Cancer Center

Merrick I. Ross, MD ¶
The University of Texas
M. D. Anderson Cancer Center

Susan M. Swetter, MD ⊖
Stanford Comprehensive Cancer
Center

Kenneth K. Tanabe, MD ¶
Massachusetts General Hospital
Cancer Center

* John A. Thompson, MD ‡
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Vijay Trisal, MD ¶
City of Hope
Comprehensive Cancer Center

Marshall M. Urist, MD ¶
University of Alabama at Birmingham
Comprehensive Cancer Center

Jeffrey Weber, MD, PhD †
H. Lee Moffitt Cancer Center &
Research Institute

Michael K. Wong, MD, PhD †
Roswell Park Cancer Institute

Continue

† Medical oncology
⊢ Internal medicine
⊖ Dermatology
¶ Surgery/Surgical oncology
≠ Pathology
¥ Patient Advocacy
‡ Hematology/Hematology oncology
* Writing Committee member

Table of Contents

[NCCN Melanoma Panel Members](#)

[Summary of Guidelines Updates](#)

[Clinical Presentation and Preliminary Workup \(ME-1\)](#)

[Stage 0 \(in situ\), Stage I-II \(ME-2\)](#)

[Stage III \(ME-3\)](#)

[Stage IV \(ME-4\)](#)

[Follow-up \(ME-5\)](#)

[Persistent disease or True local scar recurrence, In-transit recurrence \(ME-6\)](#)

[Nodal recurrence \(ME-7\)](#)

[Distant metastatic disease \(ME-8\)](#)

[Principles of Biopsy \(ME-A\)](#)

[Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-B\)](#)

[Principles of Complete Lymph Node Dissection \(ME-C\)](#)

[Systemic Therapy Options for Advanced or Metastatic Melanoma \(ME-D\)](#)

[Guidelines Index](#)

[Print the Melanoma Guideline](#)

For help using these documents, please click here

[Staging](#)

[Discussion](#)

[References](#)

This manuscript is being updated to correspond with the newly updated algorithm.

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2009.

Summary of the Guidelines Updates

Summary of changes in the 1.2010 version of the Melanoma guidelines from the 2.2009 version include:

[\(ME-1\)](#)

- Pathology Report: “Mitotic rate” changed from category 2B to category 2A.

[\(ME-2\)](#)

- Stage IB, Stage II, N0 pathway:
 - Workup: The recommendations were revised for clarity.
 - “Encourage sentinel node biopsy” changed to “Discuss and offer sentinel node biopsy”.

[\(ME-3\)](#)

- Stage III in-transit pathway; Primary Treatment: “Consider sentinel node biopsy” changed to “Consider sentinel node biopsy for resectable in-transit disease.”

[\(ME-4\)](#)

- Stage IV Metastatic; Workup: “Chest x-ray and/or chest CT” was removed.

[\(ME-5\)](#)

- The Workup recommendations for all stages were revised extensively.

[\(ME-8\)](#)

- Distant metastatic disease; Workup: “Chest x-ray, and/or chest CT” was removed.
- Disseminated; Without brain metastases: The pathways for First/Second line therapy and performance scores were removed (this information is now on page ME-D) and replaced with “Systemic therapy”.
- “With brain metastases” pathway: “Clinical trial” was removed.

[\(ME-A\): Principles of Biopsy](#)

- Sixth Bullet: “Satellitosis, if present....” changed to “Microsatellitosis, if present...”

[\(ME-B\): Principles of Surgical Margins for Wide Excision of Primary Melanoma](#)

- Footnote 2: The panel revised the footnote to read, “Clinical margins do not need to correlate with final histologic margins.”

[\(ME-D\): Systemic Therapy Options for Advanced or Metastatic Melanoma](#)

- Dacarbazine, Temozolomide, and High-dose interleukin-2 changed from “category 2B” to “category 2A”.
- Footnotes “1” and “3” are new to the page.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL
PRESENTATION

PATHOLOGY
REPORT

PRELIMINARY
WORKUP

CLINICAL STAGE



^aSee Principles of Biopsy (ME-A).


^bIf diagnostic biopsy is inadequate for treatment decisions, rebiopsy may be appropriate.

^cRisk factors for melanoma include family history of melanoma, prior primary melanoma, and other factors such as atypical moles/dysplastic nevi.

^dAdverse features include positive deep margins, lymphovascular invasion (LVI) or mitotic rate ≥ 1 per mm².

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^dAdverse features include positive deep margins, lymphovascular invasion (LVI) or mitotic rate ≥ 1 per mm².

^eDecision not to perform SLNB may be based on significant patient comorbidities, patient preference or other factors.

^fSentinel node biopsy is an important staging tool, but the impact of SLNB on overall survival is unclear.

^gSee [Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-B\)](#).


^hSentinel lymph nodes should be evaluated with multiple sectioning and immunohistochemistry.

ⁱIFN has been associated with improved DFS, however, its impact on overall survival is unclear.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Melanoma



(See Follow-up ME-5)

^gSee Principles of Surgical Margins for Wide Excision of Primary Melanoma (ME-B).
^hSentinel lymph nodes should be evaluated with multiple sectioning and immunohistochemistry.
ⁱIFN has been associated with improved DFS, however, its impact on overall survival is unclear.
^jSee Principles of Complete Lymph Node Dissection (ME-C).
^kClinical trials assessing alternatives to complete lymph node dissection, such as careful observation.
^lSee Systemic Therapy Options for Advanced or Metastatic Melanoma (ME-D).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL/
PATHOLOGIC
STAGE

WORKUP

Stage IV
Metastatic

- FNA preferred, if feasible or biopsy
- LDH
- Encourage chest/abdominal/pelvic CT, MRI brain, and/or PET as clinically indicated (category 2B)

[See Treatment for Limited \(Resectable\) or Disseminated Disease \(Unresectable\) ME-8\)](#)



Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL/
PATHOLOGIC
STAGE

FOLLOW-UP^m

RECURRENCE^o



^mCommon Follow-up Recommendations For All Patients:

- At least annual skin exam for life
- Educate patient in monthly self skin exam (and monthly self lymph node exam for Stage IA - IV NED)
- Lab tests and/or imaging are indicated to investigate for specific signs and symptoms

Follow-up schedule influenced by risk of recurrence, prior primary melanoma, and family history of melanoma, and includes other factors, such as atypical moles/dysplastic nevi, and patient anxiety.

ⁿPersistent disease or true local scar recurrence is defined by presence of in situ and/or radial growth phase.


^oLocal recurrence without in situ or radial growth phase, with deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar.

^pInitial clinical recurrence should be confirmed pathologically whenever possible.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP

TREATMENT OF RECURRENCE^P



^a See Principles of Biopsy (ME-A).

ⁱ IFN has been associated with improved DFS, however, its impact on overall survival is unclear.

^I See Systemic Therapy Options for Advanced or Metastatic Melanoma (ME-D).

ⁿ Persistent disease or true local scar recurrence is defined by presence of in situ and/or radial growth phase.

^o Local recurrence without in situ or radial growth phase, with deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar.


^P Initial clinical recurrence should be confirmed pathologically by biopsy whenever possible.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP

TREATMENT OF RECURRENCE^P



ⁱIFN has been associated with improved DFS, however, its impact on overall survival is unclear.

^jSee [Principles of Complete Lymph Node Dissection \(ME-C\)](#).

^lSee [Systemic Therapy Options for Advanced or Metastatic Melanoma \(ME-D\)](#).


^PInitial clinical recurrence should be confirmed pathologically by biopsy whenever possible.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP

TREATMENT OF METASTATIC DISEASE^P



^ISee [Systemic Therapy Options for Advanced or Metastatic Melanoma \(ME-D\)](#).

^PInitial clinical recurrence should be confirmed pathologically by biopsy whenever possible.

^QIn patients with disseminated metastases, resection or radiation may be indicated to palliate symptoms such as gastrointestinal bleeding or obstruction, ulcerated soft tissue cutaneous metastases, or bulky adenopathy.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF BIOPSY

- Excisional biopsy (elliptical, punch, or saucerization) with 1-3 mm margins preferred. Avoid wider margins to permit accurate subsequent lymphatic mapping.
- Full thickness incisional or punch biopsy¹ of clinically thickest portion of lesion acceptable, in certain anatomic areas (eg, palm/sole, digit, face, ear) or for very large lesions.
- Shave biopsy^{1,2} may compromise pathologic diagnosis and complete assessment of Breslow thickness, but is acceptable when the index of suspicion is low.
- Biopsy to be read by a pathologist experienced in pigmented lesions.
- Minimal elements to be reported should include Breslow thickness (mm), histologic ulceration, mitotic rate per mm², Clark level (optional for Breslow > 1 mm), and peripheral and deep margin status of biopsy.
- Microsatellitosis, if present, should be reported.
- Encourage consistent reporting of these additional factors (compatible with American Academy of Dermatology recommendations):
 - ▶ Location
 - ▶ Regression
 - ▶ Tumor infiltrating lymphocytes (TIL)
 - ▶ Vertical growth phase (VGP)
 - ▶ Angiolymphatic invasion
 - ▶ Neurotropism
 - ▶ Histologic subtype

¹If clinical evaluation of incisional biopsy suggests that microstaging is inadequate, consider narrow margin excision.

²For lentigo maligna, melanoma in situ, a broad shave biopsy may help to optimize diagnostic sampling.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SURGICAL MARGINS FOR
WIDE EXCISION OF PRIMARY MELANOMA**

<u>Tumor Thickness</u>	<u>Recommended Clinical Margins²</u>
In situ ¹	0.5 cm
≤ 1.0 mm	1.0 cm (category 1)
1.01 - 2 mm	1-2 cm (category 1)
2.01 - 4 mm	2.0 cm (category 1)
> 4 mm	2.0 cm

- Margins may be modified to accommodate individual anatomic or functional considerations.

¹For large melanoma in situ, lentigo maligna type, surgical margins > 0.5 cm may be necessary to achieve histologically negative margins; techniques for more exhaustive histologic assessment of margins should be considered.

²Clinical margins do not need to correlate with final histologic margins.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF COMPLETE LYMPH NODE DISSECTION

Adequacy of regional lymph node dissection:

- An anatomically complete dissection¹ of involved nodal basin is required.
- In the groin, consider elective iliac and obturator lymph node dissection if clinically positive superficial nodes or ≥ 3 superficial nodes positive. (category 2B)
- Iliac and obturator lymph node dissection indicated if pelvic CT is positive (category 2A) or if Cloquet's node is positive (category 2B).

¹Anatomic boundaries of lymph node dissection should be described in operative report.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

SYSTEMIC THERAPY OPTIONS FOR ADVANCED OR METASTATIC MELANOMA**First- or Second- Line Therapy:¹**

- Clinical trial (preferred)
- Dacarbazine
- Temozolomide
- High-dose Interleukin-2²
- Dacarbazine-or temozolomide-based combination chemotherapy/biochemotherapy, (including cisplatin and vinblastine with or without IL-2, interferon alfa) (category 2B)³
- Paclitaxel (category 2B)
- Paclitaxel/cisplatin (category 2B)
- Paclitaxel/carboplatin (category 2B)

¹In general, second line therapy is offered to patients who progress or are intolerant to first line therapy with performance status ECOG 0-2 or Karnofsky score \geq 60.

²High-dose Interleukin-2 should not be used for patients with untreated/active brain metastases.

³Multiagent regimens are complicated and associated with significant toxicities. Therapy should be restricted to an institution with medical staff experienced in the administration and management of multiagent regimens.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC MELANOMA (REFERENCES)**Dacarbazine**

- Serrone L, Zeuli M, Segal FM, et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. *J Exp Clin Cancer Res* 2000;19:21-34.

Temozolomide

- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 2000;18:158-166.

High-dose Interleukin-2

- Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008;14(17):5610-5618.

Dacarbazine or temozolomide-based combination chemotherapy or biochemotherapy including cisplatin, vinblastine, with or without interleukin-2 or interferon alfa

- Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. *J Clin Oncol* 1998;16:1752-1759.
- Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. *J Clin Oncol* 2002;20:2045-2052.
- O'Day SJ, Boasberg PD, Piro L, Kristedja TS, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. *Clin Cancer Res*. 2002(9):2775-2781.
- Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. *J Clin Oncol*. 2007 25(34):5426-5434.
- Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group. *J Clin Oncol* 2008 Dec 10; 26(35):5746-5754.

Paclitaxel

- Wiernik PH and Einzig AI. Taxol in malignant melanoma. *J Natl Cancer Inst Monogr*. 15:185-187, 1993.

Paclitaxel and carboplatin

- Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. *Cancer*. 2006;106(2):375-382.
- Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. *J Clin Oncol (Meeting Abstracts)*. 2007;25(18_suppl):8510.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Staging

Table 1

**2002 American Joint Committee on Cancer (AJCC)
TNM Staging System for Melanoma**

Primary Tumor (T)

- TX** Primary tumor cannot be assessed (e.g., shave biopsy or regressed melanoma)
- T0** No evidence of primary tumor
- Tis** Melanoma *in situ*
- T1** Melanoma ≤ 1.0 mm in thickness with or without ulceration
- T1a** Melanoma ≤ 1.0 mm in thickness and level II or III, no ulceration
- T1b** Melanoma ≤ 1.0 mm in thickness and level IV or V or with ulceration
- T2** Melanoma 1.01 -- 2.0 mm in thickness with or without ulceration
- T2a** Melanoma 1.01 -- 2.0 mm in thickness, no ulceration
- T2b** Melanoma 1.01 -- 2.0 mm in thickness, with ulceration
- T3** Melanoma 2.01 -- 4.0 mm in thickness with or without ulceration
- T3a** Melanoma 2.01 -- 4.0 mm in thickness, no ulceration
- T3b** Melanoma 2.01 -- 4.0 mm in thickness, with ulceration
- T4** Melanoma > 4.0 mm in thickness with or without ulceration
- T4a** Melanoma > 4.0 mm in thickness, no ulceration
- T4b** Melanoma > 4.0 mm in thickness, with ulceration

Regional Lymph Nodes (N)

- NX** Regional lymph nodes cannot be assessed
- N0** No regional lymph node metastasis
- N1** Metastasis in one lymph node
- N1a** Clinically occult (microscopic) metastasis
- N1b** Clinically apparent (macroscopic) metastasis
- N2** Metastasis in two or three regional nodes or intralymphatic regional metastasis without nodal metastases
- N2a** Clinically occult (microscopic) metastasis
- N2b** Clinically apparent (macroscopic) metastasis
- N2c** Satellite or in-transit metastasis without nodal metastasis
- N3** Metastasis in four or more regional lymph nodes, or matted metastatic nodes, or in-transit metastasis or satellite(s) with metastasis in regional node(s)

Distant Metastasis (M)

- MX** Distant metastasis cannot be assessed
- M0** No distant metastasis
- M1** Distant metastases
- M1a** Metastasis to skin, subcutaneous tissue, or distant lymph nodes
- M1b** Metastasis to lung
- M1c** Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum lactic dehydrogenase (LDH)

[Continue](#)

Staging, continued

Clinical Stage Grouping

Stage 0	Tis	N0	M0
Stage IA	T1a	N0	M0
Stage IB	T1b	N0	M0
	T2a	N0	M0
Stage IIA	T2b	N0	M0
	T3a	N0	M0
Stage IIB	T3b	N0	M0
	T4a	N0	M0
Stage IIC	T4b	N0	M0
Stage III	Any T	N1	M0
	Any T	N2	M0
	Any T	N3	M0
Stage IV	Any T	Any N	M1

Note: Clinical staging includes microstaging of the primary melanoma and clinical/radiological evaluations for metastases. By convention, it should be used after complete excision of the primary melanoma with clinical assessment for regional and distant metastases.

Histopathologic Type

- Melanoma in situ
- Malignant melanoma, NOS
- Superficial spreading melanoma
- Nodular melanoma
- Lentigo maligna melanoma
- Acral lentiginous melanoma
- Desmoplastic melanoma
- Epithelioid cell melanoma
- Spindle cell melanoma
- Balloon cell melanoma
- Blue nevus, malignant
- Malignant melanoma in giant pigmented nevus

Pathologic Stage Grouping

Stage 0	Tis	N0	M0
Stage IA	T1a	N0	M0
Stage IB	T1b	N0	M0
	T2a	N0	M0
Stage IIA	T2b	N0	M0
	T3a	N0	M0
Stage IIB	T3b	N0	M0
	T4a	N0	M0
Stage IIC	T4b	N0	M0
Stage IIIA	T1–4a	N1a	M0
	T1–4a	N2a	M0
Stage IIIB	T1–4b	N1a	M0
	T1–4b	N2a	M0
	T1–4a	N1b	M0
	T1–4a	N2b	M0
	T1–4a/b	N2c	M0
Stage IIIC	T1–4b	N1b	M0
	T1–4b	N2b	M0
	Any T	N3	M0
Stage IV	Any T	Any N	M1

Note: Pathologic staging includes microstaging of the primary melanoma and pathologic information about the regional lymph nodes after partial or complete lymphadenectomy. Pathologic Stage 0 or Stage IA patients are the exception; they do not require pathologic evaluation of their lymph nodes.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit www.cancerstaging.net.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 01/21/09

NCCN Categories of Evidence and Consensus

Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

Category 3: The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

In the year 2008, an estimated 62,480 new cases of melanoma will be diagnosed and about 8,420 patients will die of the disease in the United States.¹ However, these estimates for new cases may represent a substantial underestimation, because many superficial and in-situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically. Melanoma is increasing in men more rapidly than any other malignancy and, in women more rapidly than any other malignancy except lung cancer. The lifetime risk of developing melanoma in the year 2005 for someone born in the United States may be as high as one in 55.² Melanoma ranks second to adult leukemia in terms of loss of years of potential life, per death. The median age at diagnosis is 59 years.

Risk factors for melanoma include a positive family history of melanoma, prior melanoma, multiple clinically atypical moles or dysplastic nevi,^{3,4} and inherited genetic mutations. In addition to genetic factors, sun exposure may also contribute to the development of melanoma.⁵ Individuals with an inability to tan and fair skin that sunburns easily have a greater risk of developing melanoma.^{6,7} However, melanoma can occur in any ethnic group and also in areas of the body without substantial sun exposure.

As with nearly all malignancies, the outcome of melanoma initially depends on the stage at presentation.⁸ It is estimated that 82-85% of melanoma patients present with localized disease, 10-13% with regional disease, and 2-5% with distant metastatic disease. In general, the prognosis is excellent for patients who present with localized disease and primary tumors 1.0 mm or less in thickness, with 5-year survival achieved in more than 90% of patients. For patients with localized melanomas more than 1.0 mm in thickness, survival rates range from 50-90%. The likelihood of regional nodal involvement increases with increasing tumor thickness. When regional nodes are involved, survival rates are roughly halved. However, within stage III, 5-year survival rates range from 20-70%, depending primarily on the nodal tumor burden. Long-term survival in patients with distant metastatic melanoma, taken as a whole, is less than 10%. However, even within stage IV, some patients have a more indolent clinical course that is biologically quite distinct from most patients with advanced disease.

By definition, the National Comprehensive Cancer Network (NCCN) practice guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among the members of the panel during the process of developing these guidelines. A 5% rule (omitting clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical

occurrences or conditions from these guidelines. The NCCN Melanoma Panel strongly supports early diagnosis and appropriate treatment of melanoma.

Clinical Presentation and Workup

Biopsy

Patients presenting with a suspicious pigmented lesion optimally should undergo an excisional biopsy, preferably with 1-3 mm margins. The orientation of the excisional biopsy should always be planned with definitive treatment in mind (eg, a longitudinal orientation in the extremities). With the increasing use of lymphatic mapping and sentinel node biopsy, biopsies should also be planned so they will not interfere with this procedure. In this regard, wider margins for the initial diagnostic procedure should be avoided.

Excisional biopsy may be inappropriate for certain sites (including the face, palmar surface of the hand, sole of the foot, ear, distal digit, or subungual lesions) or for very large lesions. In these instances, a full-thickness incisional or punch biopsy of the clinically thickest portion of the lesion, rather than a shave biopsy, is an acceptable option. These procedures should provide accurate primary tumor microstaging, without interfering with definitive local therapy. If the incisional biopsy is inadequate to make a diagnosis or to accurately microstage the tumor (based on evaluation by a dermatopathologist) for treatment planning, re-biopsy with narrow margin excision should be considered.

Pathology Report

In the revised American Joint Committee of Cancer (AJCC) staging system, melanoma patients are categorized into three groups: localized disease with no evidence of metastases (stage I-II), regional disease (stage III) and distant metastatic disease (stage IV).^{8,9} Breslow tumor thickness and ulceration are the two most important characteristics of the primary tumor predicting outcome in patients with localized

melanoma (stage I or II).¹⁰ In the most recent version of the AJCC staging system, Clark level was also a strong independent predictor of outcome, for primary melanomas less than 1 mm thick.⁸

Mitotic rate (MR) is an indicator of tumor proliferation and is measured as the number of mitoses per mm². Barnhill et al compared the relative importance of MR vs. ulceration as major prognostic factors in localized melanoma.¹¹ In a multivariate analysis including MR and ulceration, tumor thickness, moderate MR (between 1 and 6) and MR greater than 6 emerged as the most important independent prognostic factor. Several other studies have also confirmed the prognostic importance of MR in patients with primary cutaneous melanoma.¹²⁻¹⁴ In multivariate analyses MR and younger age were identified as independent predictors of a positive sentinel lymph node (SLN), in addition to Breslow thickness.^{15,16}

The American Academy of Dermatology (AAD) Task Force recommends the inclusion of MR in the biopsy report as optional along with other additional factors such as vertical growth phase (VGP), tumor-infiltrating lymphocytes (TIL) and regression.¹⁷ Microscopic satellitosis, if present, should also be recorded, as this defines a patient subgroup at high risk for regional and systemic failure, prognostically similar to Stage III.

For Stage I-II patients, the NCCN melanoma panel recommends the inclusion of Breslow thickness, ulceration status, mitotic rate, deep and peripheral margin status, satellitosis if present and Clark level (especially for lesions 1.0 mm or less) in the pathology report. Mitotic rate should be reported for all lesions, as it is emerging as an independent predictor of outcome (category 2B). The panel agreed that recording of those parameters identified by the AAD task force would be helpful, but not mandatory.

Among patients with localized melanoma undergoing sentinel lymph node biopsy (SLNB), the status of the sentinel node is the most important prognostic factor.¹⁰ Among patients with nodal metastases (stage III), the number of metastatic nodes and clinical nodal status (nonpalpable vs. palpable) are the most important predictors of survival, followed by the presence or absence of primary tumor ulceration. Other prognostically relevant factors include the presence of extranodal tumor extension and, in patients with positive sentinel nodes, the size and location of the metastatic melanoma in the sentinel nodes.

For Stage III patients, the NCCN melanoma panel recommends reporting the number of positive nodes, the total number of nodes examined, and the presence or absence of extranodal tumor extension. In addition, the panel recommends recording the size and location of tumor present in a positive sentinel node.

The site of metastases is the most significant predictor of outcome among patients with distant metastases (Stage IV). Elevated LDH is also an independent predictor of poor outcome in patients with stage IV disease and has been incorporated into the AJCC staging system.^{10,18}

For Stage IV patients, the NCCN melanoma panel recommends reporting all sites of metastatic disease, and the serum LDH at diagnosis of Stage IV.

Preliminary Workup

After the diagnosis of melanoma has been confirmed, a history and physical examination (H&P) as well as a complete dermatologic examination are recommended. Preliminary work up of patient presenting with dysplastic nevi should include detailed personal and family history including any history of prior removal of dysplastic nevi.³ In the physical examination of patients with invasive melanoma, physicians should pay special attention to the locoregional area and lymph node drainage of the established melanoma.

Clinical Staging

Patients can be clinically staged after histopathologic microstaging, an H&P including examination of locoregional area and draining lymph nodes, and a complete skin examination. In accordance with the AJCC staging system, NCCN guidelines have categorized patients into the following clinical groups:

- Stage 0 (melanoma in situ)
- Stage IA, (1.0 mm or less, Clark level II-III) with or without potentially adverse features such as positive deep margins, lymphovascular invasion and mitotic rate greater than or equal to 1 per mm²;
- Stage IB-II (1.0 mm or less with ulceration or Clark level IV-V; or greater than 1.0 mm, with any characteristic and clinically negative nodes);
- Stage III, clinically positive nodes
- Stage III, in-transit disease;
- Stage IV, distant metastatic disease;

Pathologic Staging

Patients with clinically localized stage I-II melanoma may be further pathologically staged by lymphatic mapping with sentinel lymph node biopsy. Depending on the primary tumor thickness, ulceration, and other factors described above, 5 – 30% of patients undergoing SLNB will be upstaged from clinical stage I-II to pathologic stage III, based on subclinical micrometastatic disease in the SLN. These patients have a distinctly better prognosis than those patients with clinically positive nodes containing macrometastatic disease.^{10,19} The AJCC staging system clearly recognizes this difference in prognosis among patients with pathologic stage III melanoma.⁸

Workup

There are several reasons to embark on an extent of disease workup in the melanoma patient. One would be to establish a set of baseline images against which to compare future studies in a patient at risk for relapse. Another would be to detect clinically occult disease that would affect immediate treatment decisions. A third reason would be to define homogeneously staged patients for inclusion into clinical trials.

Although patients greatly value the negative result of a cross-sectional imaging study, physicians need to be cautious about over interpreting the significance of the findings, recognizing that all tests have relatively insensitive lower limits of resolution. Finally, any test that is ordered has with it the very real possibility of detecting findings unrelated to the melanoma, findings that can lead to morbid invasive biopsy procedures, or at the very least substantial patient anxiety incurred while awaiting results of interval follow-up studies.

The yield of routine blood work and imaging studies in screening patients with clinical stage I-II melanoma for asymptomatic distant metastatic disease is very low. Screening blood tests are very insensitive, and the findings of cross-sectional imaging are often nonspecific, with frequent “false positive” findings unrelated to melanoma.²⁰⁻²²

The yield of imaging studies has been more extensively evaluated in the context of patients with Stage III melanoma. In patients with a positive SLN, the yield of cross-sectional imaging in detecting clinically occult distant metastatic disease ranges from 0.5-3.7%.²³⁻²⁵ All series report a high rate of indeterminate and false positive findings. True positive findings are most often found in patients with ulcerated thick primary tumors with large tumor burden in their sentinel nodes. In asymptomatic patients with clinically positive nodes, the yield of routine cross sectional imaging is a bit higher than in patients with positive

sentinel nodes, reported at 4-16%.²⁶⁻²⁸ These series also report a high incidence of radiologic findings that are unrelated to melanoma.

These retrospective studies are reporting minimum estimates, as it is very difficult to define a study population of truly “imaging-naïve” Stage III patients. It is probable that, among the entire denominator of Stage III patients, some would have been defined as stage IV based on imaging before the study cohort was assembled. Furthermore, as the majority of clinical Stage III patients will ultimately develop distant metastases, the inability of computed tomography (CT) scans to detect this at diagnosis of stage III is a relatively poor predictor of future events.

Positron emission tomography (PET) scanning has attracted interest as a means of enhancing detection of subclinical metastatic disease. Most investigators have described very low yield and poor sensitivity in detecting metastatic disease in patients with clinically localized melanoma.²⁹⁻³¹ In patients with more advanced stage III disease, PET scan may be more useful. In particular, PET scans can help to characterize lesions found to be indeterminate on CT scan, and often image areas of the body not studied by the routine body CT scans (ie. arms and legs).³²

NCCN Recommendations

Practices among the NCCN member institutions vary greatly with respect to the appropriate workup of a melanoma patient. In the absence of compelling data beyond the retrospective series cited above, for the most part, the extent of workup is left to the discretion of the treating physician.

Routine imaging studies such as a CT scan, PET scan, or magnetic resonance imaging (MRI) are not recommended for patients with localized thin melanomas (stage I). NCCN recommendation is consistent with National Institutes of Health (NIH) consensus

guidelines.³³ However, these tests may be performed as clinically indicated to evaluate specific signs or symptoms in patients with stage II melanoma. A baseline chest x-ray is optional for patients with stage IB-II melanoma, because this test is insensitive for detecting clinically occult distant metastases in the lungs.

Most panel members acknowledged the low yield of screening CT or PET scans in patients with Stage III melanoma. Based on the results of the studies reported in the literature and the absence of conclusive data, the panel left the extent of scanning to the discretion of the treating physician. For patients presenting with clinical stage III disease who have clinically positive node(s), all panel members believe it is appropriate to confirm the suspicion of regional metastatic disease, preferably with fine-needle aspiration (FNA) or open biopsy of the clinically enlarged lymph node. Clearly, in patients without an antecedent history of melanoma, this would have been the initial diagnostic test. A pelvic CT scan is recommended in the setting of inguinofemoral lymphadenopathy to rule out associated pelvic or retroperitoneal lymphadenopathy.

For the small group of patients presenting with stage III in-transit disease, the workup just outlined for stage III nodal disease, including histologic confirmation of the in-transit metastasis, is appropriate .

For patients presenting with stage IV distant metastatic disease, all panel members agree it is appropriate to confirm the suspicion of metastatic disease with either FNA (preferred) or with open biopsy of the lesion. LDH level plus chest x-ray and/or chest CT are recommended. Abdominal/pelvic CT, with or without PET, and/or head MRI should be considered (category 2B).

Because patients with metastatic melanoma have a high incidence of brain metastases, brain MRI or CT scan with contrast should be performed if patients have even minimal suggestions of symptoms or

physical findings of central nervous system (CNS) involvement, or if results of imaging would affect decisions about treatment.

Although LDH is not a sensitive marker for detecting metastatic disease, the panel recognizes its prognostic role. It is recommended that serum LDH be obtained at diagnosis of Stage IV disease. Other blood work may be done at the discretion of the treating physician.

Treatment of Primary Melanoma

Wide Excision

Surgical excision is the primary treatment for melanoma. Several prospective randomized trials have been conducted in an effort to define optimal surgical margins for primary melanoma.

In an international prospective study carried out by the World Health Organization (WHO), 612 patients with primary melanomas not thicker than 2.0 mm were randomized to wide excision with one cm or three cm margins.^{34,35} At a median follow-up of 90 months, local recurrence, disease-free and overall survival rates were similar in both groups.

The National Intergroup Trial randomized 468 patients with melanomas that are 1.0-4.0 mm in thickness to wide excision with either two or four cm margins. At a median follow-up of ten years, there were no differences in local recurrence, disease-free, or overall survival.^{36,37} Prospective randomized trials from Sweden have confirmed that satisfactory local control and melanoma specific survival are not compromised by narrower margins.^{38,39}

In a more recent prospective randomized trial comparing 1 cm vs. 3 cm margins for melanomas thicker than 2 mm, wider margins were associated with a slightly lower rate of combined local/regional/nodal recurrence, but without improvement in local recurrence alone, or in melanoma specific survival.⁴⁰ A systemic review and meta-analysis also reported that surgical excision margins no more than 2 cm are

adequate and surgical margins should not be less than 1 cm around primary melanoma.⁴¹

Management of lentigo maligna melanoma may present unique problems because of the characteristic, yet unpredictable, subclinical extension of atypical junctional melanocytic hyperplasia which may extend several centimeters beyond the visible margins. Various approaches aimed at complete surgical excision with meticulous margin control, have demonstrated high local control rates and are used at some NCCN centers, although they are not universally accepted.^{42,43}

NCCN Recommendations

The NCCN recommendations for surgical margins for wide excision are based on the results of clinical trials discussed above. In cases where there were no prospective data available (in situ and thick melanoma), recommendations were made based on consensus. Note that the clinical/surgical margins discussed here do not necessarily correlate with gross pathological/histological margins.

For in-situ melanoma, a measured margin of 0.5 cm around the visible lesion should be obtained. For large in situ lentigo maligna melanoma, surgical margins greater than 0.5 cm may be necessary to achieve histologically negative margins. For patients with stage IA melanoma (1.0 mm or less), wide excision with a 1.0 cm margin is recommended (category 1).

Wide excision with a 1-2 cm margin is recommended for patients with melanomas measuring 1.01-2.0 mm in thickness (category 1). For melanomas measuring more than 2.0 mm in thickness, wide excision with 2.0 cm margins is recommended (category 1 for tumors 4 mm or less in thickness; category 2A for tumors more than 4 mm in thickness). Surgical margins may be modified to accommodate individual anatomic or cosmetic considerations. The panel recognized that 1-2 cm margins

might be acceptable in anatomically difficult areas where a full 2.0 cm margin would be difficult to achieve.

Although surgical excision remains the standard of care for in situ melanoma, it is sometimes not feasible due to comorbidity or cosmetically-sensitive tumor location. Topical imiquimod has emerged as a treatment option, especially for lentigo maligna.⁴⁴⁻⁴⁷ However, long-term, comparative studies are still needed and the panel currently did not include specific recommendations for this treatment option for in situ melanoma.

Sentinel Lymph Node Biopsy

SLNB is a minimally invasive procedure developed to identify patients with nodal metastases and who could be candidates for complete lymph node dissection.⁴⁸ MSLT- I, an international multicenter phase III trial, was initiated to evaluate the accuracy, morbidity and use of lymphatic mapping and SLNB for staging patients with early stage melanoma.⁴⁹ In a preliminary publication, Morton et al reported an initial sentinel node identification rate of 95%. SLNB was also associated with a low false negative rate and low complication rate.

Recently, Morton et al published data from the third interim analysis of results from the MSLT-I trial.⁵⁰ In patients with intermediate thickness primary melanoma (1.2-3.5 mm), those undergoing wide excision with SLNB (and completion lymph node dissection if their sentinel nodes were positive) had no significant improvement in melanoma-specific survival rates compared to those undergoing initial wide excision and nodal observation and delayed therapeutic lymphadenectomy if necessary. There was an improvement in the estimated 5-year disease-free survival in the SLNB group (78% after SLNB vs. 73% after observation (P= 0.009); this was at least in part due to the higher nodal relapse rate in the observation group. Among patients undergoing SLNB, the sentinel node status was the most important prognostic

factor for disease specific survival. Furthermore, among all patients with nodal metastases, those who had immediate lymph node dissection following lymphatic mapping and positive SLNB had higher survival rate than patients who underwent delayed lymphadenectomy for clinical disease (72% vs. 52%). This difference was largely attributed to a lower nodal tumor burden in the SLN positive patients than the clinically node positive patients. These results confirm that SLNB is of prognostic value and that the procedure can identify patients with low volume nodal metastases whose survival is superior to that of patients whose nodal metastases are detected on clinical examination.

MSLT-II is an ongoing trial in which patients with sentinel node metastases are randomized to undergo either completion lymph node dissection or observation. This trial should resolve the issue of whether complete lymph node dissection has an impact on outcome. (clinicaltrials.gov/show/NCT00297895).

The value of SLNB for patients with thin melanomas (1.0 mm or less) and thick melanomas (4.0 mm or greater) was not addressed specifically in the MSLT-I trial. Since patients with thin melanoma have a generally favorable prognosis, the role of SLNB in this cohort is unclear. Three recent retrospective reviews have shown that, for patients with melanomas less than or equal to 1 mm thick, the incidence of positive SLN is 2-5%.⁵¹ Factors predicting an increased probability of a positive SLN in patients with thin melanomas include increasing Breslow thickness and Clark level, higher mitotic rate, and younger age. However, with relatively short follow-up, only one center has demonstrated any convincing evidence that the SLN status was predictive of outcome in this low risk group of patients.⁵² Larger series and longer term follow-up will be required to assess the prognostic value of the SLN in patients with thin melanoma.⁵³⁻⁵⁵

The probability of a positive sentinel node in patients with thick melanoma, 4 mm or greater, is 30-40%. Almost every retrospective

series has demonstrated that SLN status is a strong independent predictor of outcome in patients with thick melanoma.⁵⁶⁻⁵⁸ Thus, in these high-risk patients, it would seem reasonable to offer SLNB, to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy.

NCCN Recommendations

Sentinel node biopsy may be offered to melanoma patients either as standard care or in the context of a clinical trial. The NCCN melanoma panel does not recommend SLNB for patients with in situ melanoma (stage 0) or stage IA melanoma that is 1.0 mm or less with no adverse features. Discussion of SLNB should be considered for patients with stage IA thin melanomas (1.0 mm or less) with adverse prognostic features such as thickness over 0.75 mm, high mitotic rate, and young patient age. Other factors such as positive deep margins and lymphovascular invasion could be considered indications for SLNB on an individual basis (Category 2B).⁵⁹⁻⁶² The significance of tumor regression is debatable, with more recent studies reporting no association of regression incidence to increased SLN positivity.^{63,64} As the yield of a positive sentinel node biopsy in patients with Stage IA melanoma is low and the clinical significance of a positive SLN in these patients remains unclear, any discussion of the procedure in this patient population should reflect those facts. For patients with stage IB or stage II melanoma (1.0 mm thick or less with ulceration or Clark level IV,V or if the lesions are more than 1.0 mm thick, the panel encourages the use of SLNB. However, while SLNB is a useful staging tool, its impact on the overall survival of these patients is unclear. In patients who would be candidates for SLNB, the decision to not perform SLNB may be based on significant patient comorbidities or patient preference.

Sentinel nodes should be evaluated with serial sectioning and immunohistochemistry. The validity of sentinel node biopsy in accurately staging patients after prior wide excision is unknown. As

such, wide excision before planned sentinel node biopsy is discouraged, although patients may be considered for sentinel node biopsy on an individual basis if they present after initial wide excision. The panel had a substantial discussion about the appropriate management of clinically negative lymph nodes in patients at risk for regional metastases, in the event that SLNB is unavailable. Based on the results of three prospective randomized trials, the panel does not recommend routine elective lymph node dissection for this group. Wide excision alone or referral to a center where lymphatic mapping is available are both acceptable options in this situation.

Lymph Node Dissection

Complete lymph node dissection consists of an anatomically complete dissection of the involved nodal basin. The extent of complete lymph node dissection is often modified according to the anatomic area of lymphadenopathy. In the absence of clinical or radiologic evidence of deep node involvement, patients with melanoma metastatic to inguinal nodes are at risk for pelvic node involvement when there are more than three superficial nodes involved, if the nodes are clinically positive, or if Cloquet's node is positive.⁶⁵⁻⁶⁷

NCCN Recommendations

If the sentinel node is negative, regional lymph node dissection is not indicated. Patients with stage III disease based on a positive SLN should be offered a complete lymph node dissection of the involved nodal basin, either as a standard of care or in the context of a clinical trial. Published studies have revealed additional positive non-sentinel nodes in approximately 20% of these complete lymph node dissection specimens.^{68,69} However the impact of completion lymph node dissection on regional control and survival in this setting has not been clearly demonstrated. Participation in MSLT-II, assessing the option of nodal observation in patients with positive sentinel nodes, is encouraged where available.

Patients presenting with clinical Stage III and clinically positive nodes, without radiologic evidence of distant metastases, should undergo wide excision of the primary site (if present) and complete lymph node dissection of the involved nodal basin. In the setting of inguinal lymphadenopathy, a deep groin dissection is recommended if the PET or pelvic CT scan reveals iliac and/or obturator lymphadenopathy or if a positive Cloquet's lymph node is found intraoperatively.^{66,67} Deep groin dissection also should be considered for clinically positive nodes or if more than three superficial nodes are involved.⁶⁵

One measure of the completeness of a regional lymph node dissection is the number of lymph nodes examined. However, the NCCN committee felt that available retrospective evidence to date was insufficient to mandate that a specific number of nodes be required to deem a lymph node dissection adequate. As a measure of quality control to ensure adequacy of lymphadenectomy, the committee recommended that the operative note fully describes the anatomic boundaries of the lymph node dissection.

Adjuvant Treatment for Melanoma

Low-Dose and Intermediate-Dose Interferon

In the first major randomized trial conducted by WHO,⁷⁰ there was no significant improvement in the overall survival (35% for the interferon group vs. 37% for those assigned to observation alone). In the French Cooperative Group trial, after a median follow-up of 5 years, adjuvant interferon therapy showed a significant relapse-free survival benefit and also a trend towards an increase in overall survival.⁷¹ In another prospective randomized study, adjuvant interferon prolonged disease-free survival for all patients at the median follow-up of 41 months.⁷²

Two other randomized clinical trials (EORTC 18952 and AIM HIGH Study) compared adjuvant interferon with observation in patients with

resected stage IIB and stage III melanoma. In AIM HIGH Study, low-dose interferon alfa-2a did not improve either overall survival or recurrence-free survival.⁷³ No significant improvement in progression-free survival was reported for intermediate-dose interferon alfa-2b in EORTC 18952.⁷⁴

High-Dose Interferon

High dose interferon has been evaluated in three randomized clinical trials. ECOG 1684 trial compared high dose interferon alfa-2b with observation in patients with stage IIB (4.0 mm or thicker with no evidence of lymph node involvement) and stage III melanomas with either regional lymph node disease or in transit metastases. At a median follow-up of 6.9 years, a statistically significant improvement in survival was demonstrated for patients in the interferon group. However, at 12.6 years of follow-up, overall survival was not significantly different between the two groups, even though there was a significant benefit for relapse free survival.⁷⁵ The results of a larger follow-up trial, ECOG 1690, also showed a relapse-free survival advantage, but no overall survival advantage, for high-dose interferon alfa-2b.⁷⁶ E1694 compared high-dose interferon alfa-2b with an experimental vaccine. At approximately 2 years of median follow-up, the interferon alfa-2b group showed a statistically significant improvement in relapse-free survival and overall survival.⁷⁷

A recent retrospective review of 200 patients with melanoma (stage IIB, IIC, or III) reported that those who had autoantibodies or clinical manifestations of autoimmunity after treatment with high-dose interferon alfa-2b had improved survival (both relapse free and overall survival).⁷⁸

Review of data combined from the randomized controlled trials found that adjuvant interferon alfa was not associated with improved overall survival in patients with melanoma who were at increased risk for

recurrence.⁷⁹ A pooled analysis of E1684, E1690 and E1694 confirmed an improvement in relapse-free survival in patients with high risk resected melanoma (two-sided log-rank P value = .006) but did not find a significant improvement in overall survival.⁸⁰

ECOG studies discussed above included patients with stage IIB (4.0 mm or thicker with no evidence of lymph node involvement) and stage III melanomas with either regional lymph node disease or in transit metastases. In a recent systematic review, the authors concluded that even though high dose interferon alfa is associated with improved disease free survival in high-risk primary melanomas, the role of adjuvant interferon for patients with intermediate to high-risk melanoma remains undefined.⁸¹

NCCN Recommendations

Most patients with in-situ or early-stage melanoma will be cured by primary excision alone. For patients with in-situ or node-negative primary melanoma (stage IA, 1 mm thick or less with or without adverse features), no standard adjuvant therapy is recommended. For patients with node-negative early stage melanoma who are at risk for recurrence (stage IB or stage II, 1.0 mm thick or less with ulceration or Clark level IV-V, or 1.0 mm thick or more) adjuvant treatment options include a clinical trial or observation. For patients with node negative stage IIB or IIC disease, adjuvant treatment options include clinical trial, interferon alfa, or observation. For patients with stage III melanoma, adjuvant treatment options include clinical trial, interferon alfa, or observation.

Treatment with adjuvant interferon alfa is a category 2B recommendation. Decisions about the appropriateness of adjuvant interferon alfa-2b treatment for patients should be made on an individual basis, after discussion with the patient, including an

explanation of the potential benefits and side effects of interferon therapy.⁸²⁻⁸⁴

Adjuvant hypofractionated RT to the nodal bed should be considered (category 2B) for stage IIIC patients in the setting of multiple positive nodes or extranodal soft-tissue extension, especially in the head and neck region. However, this recommendation is based on retrospective, uncontrolled observations rather than on prospective, randomized data.^{85,86}

For all patients who have been rendered free of disease by surgery, following initial treatment for recurrent or metastatic disease (stage III in-transit metastases or stage IV), consideration of adjuvant treatment is appropriate. The guidelines recommend clinical trial, interferon alfa (category 2B), or observation as adjuvant treatment options.

Treatment of Metastatic Melanoma

Metastatic melanoma is associated with a poor prognosis. Several chemotherapeutic agents, including dacarbazine and temozolomide, have shown activity in patients with metastatic melanoma when used as single agents or in combination chemotherapy regimens.⁸⁷ However, little consensus currently exists regarding standard therapy for patients with metastatic melanoma, which most likely reflects the low level of activity of all available agents.^{88,89}

Dacarbazine still remains a standard of care in community practice, and has been used as a standard for comparing the efficacy of new regimens.⁹⁰ A small randomized trial has demonstrated similar response rates and survival for dacarbazine and temozolomide treatment of metastatic melanoma.⁹¹ Both dacarbazine and temozolomide result in response rates of approximately 10-20%, with median response duration of 3-4 months.^{87,91}

Initial reports of combination chemotherapy regimens such as CVD (dacarbazine plus cisplatin and vinblastine) or Dartmouth regimen (dacarbazine, carmustine, cisplatin and tamoxifen) suggested high response rates.^{92,93} Subsequent clinical trials have not replicated these high response rates. In phase III randomized trial, survival following treatment with Dartmouth regimen was not superior to dacarbazine alone.⁹⁴

Paclitaxel alone or in combination with carboplatin may provide clinical benefit to some patients with metastatic melanoma; however, the duration of clinical benefit is short (2-7 months).^{95,96}

Interleukin-2 (IL-2) was approved by the Food and Drug administration (FDA) for treatment of metastatic melanoma in 1998. High dose intravenous bolus IL-2 treatment resulted in overall objective response rates of about 12-21%. In a highly selected patient population, IL-2 was able to induce durable complete responses in approximately 6% of patients and partial responses in 10% of patients with metastatic melanoma, albeit with high levels of toxicity.⁹⁷ A recent study demonstrated increased response rate in metastatic melanoma when IL-2 was given with the 210M peptide vaccine (22%) compared to IL-2 (13%) alone.⁹⁸

Biochemotherapy is the combination of chemotherapy and biological agents. In initial single institutional phase II trials, biochemotherapy (cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2) produced an overall response rate of 64% and a complete response rate of 21% in patients with metastatic melanoma.^{99,100} A report of a small phase III randomized trial comparing sequential biochemotherapy (dacarbazine, cisplatin, vinblastine with interleukin-2 and interferon alfa administered on a distinct schedule) with CVD showed response rates of 48% for biochemotherapy regimen compared to 25% for CVD alone; median survival for patients treated with biochemotherapy was 11.9 months vs. 9.2 months for CVD.¹⁰¹ In a phase III randomized intergroup

trial (E3695), biochemotherapy (cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alpha-2b) produced a slightly higher response rate and progression free survival than CVD alone; but it was not associated with either improved quality of response or overall survival in patients with metastatic melanoma.¹⁰² Biochemotherapy was substantially more toxic than CVD. Additional attempts to decrease toxicity of biochemotherapy by administering subcutaneous outpatient IL-2 did not show a substantial benefit of biochemotherapy versus chemotherapy alone.¹⁰³⁻¹⁰⁵ Recent report from a meta-analysis also showed that although biochemotherapy improves overall response rates, there was no survival benefit for patients with metastatic melanoma.¹⁰⁶

NCCN Recommendations

Stage III: In-transit metastases

Many different treatment options are available for patients presenting with stage III in-transit metastases. For those with a one or a small number of in-transit metastases, complete surgical excision with histologically negative margins is preferred (category 2B), if feasible. In the patient undergoing curative resection of a solitary in-transit metastasis, sentinel node biopsy (category 2B) can be considered because of the high probability of occult nodal involvement.¹⁰⁷ Although a positive sentinel node in the presence of in-transit metastasis portends a more ominous prognosis, the impact of sentinel node biopsy on outcome is unproven.

If the patient has a limited number of in-transit metastases, particularly dermal lesions, which are not amenable to complete surgical excision, intralesional local injections with bacillus Calmette-Guérin (BCG)¹⁰⁸ or interferon-alfa, or topical imiquimod¹⁰⁹ can be considered (category 2B for all of the options). Laser ablation may be used in selected patients (category 2B).

Isolation limb infusion has been reported by Thompson et al to be a simpler technique with response rates comparable to limb perfusion.¹¹⁰ The panel has included hyperthermic isolated limb perfusion or infusion as one of the treatment options for patients with unresectable in-transit metastases (category 2B).¹¹¹⁻¹¹³

Radiation therapy is included as a treatment option (category 2B), recognizing its relative inefficiency in controlling regional disease. Other alternatives include systemic therapy (particularly after failure of local and/or regional therapy) or treatment in the context of a clinical trial.

Distant metastatic disease (Stage IV)

Treatment for stage IV metastatic melanoma depends on whether disease is limited (resectable) or disseminated (unresectable) as outlined below. Clinical trial is the preferred treatment option for patients with distant metastatic disease.

Resection, if feasible, followed by adjuvant treatment with interferon alfa is recommended for limited metastatic disease.¹¹⁴ In selected patients with a solitary site of visceral metastatic melanoma, a short period of observation or systemic treatment followed by repeat scans may be appropriate to rule out the possibility that the visceral metastasis is the first of many metastatic sites and to better select patients for surgical intervention. Following observation, patients with resectable solitary sites of disease should be assessed for surgery. If resected, patients can be offered adjuvant treatment with interferon alfa or clinical trial (category IIB). Alternatively, limited metastatic disease can be treated with systemic therapy either as a standard of care or in the context of a clinical (preferred). Residual disease following incomplete resection for limited metastases is treated as described below for disseminated disease. Systemic therapy options are listed in the following paragraph.

Disseminated disease is treated based on the presence or absence of brain metastases. For patients without brain metastases, options for systemic therapy include:

- single-agent chemotherapy (dacarbazine, temozolomide or paclitaxel) or high-dose interleukin-2;
- combination chemotherapy (paclitaxel with cisplatin or carboplatin);
- combination chemotherapy or biochemotherapy (dacarbazine or temozolomide-based including cisplatin and vinblastine, with or without interleukin-2, interferon alfa);

All of the above options are category 2B recommendations.

For patients with disseminated melanoma that is unresponsive to, or relapsing after first line systemic therapy, additional systemic therapy may be indicated if the patient has performance status 0-2. Options for second-line therapy include clinical trial (preferred) or treatment with a different agent from the list of first-line options indicated above. In addition to systemic therapy, surgical resection or radiation may be considered for palliation and management of symptoms, such as gastrointestinal bleeding or obstruction, ulcerated soft tissue cutaneous metastases or bulky adenopathy.

For patients with brain metastases, treatment of the CNS disease usually takes priority, in an effort to delay or prevent intratumoral hemorrhage, seizures, or neurological dysfunction. Treatment for patients with brain metastases is based on symptoms, number of lesions present, and location of the lesions, as described in [NCCN Central Nervous System Cancers Guidelines](#). In patients with both brain and extracranial metastases, therapy as outlined in the preceding paragraph may be administered during or after treatment of the CNS disease.

Follow-up

In the absence of any clear data, opinions vary widely regarding the appropriate follow-up of patients with melanoma. The follow-up schedule is influenced by risk of recurrence, previous primary melanoma, and family history of melanoma; it includes other factors, such as dysplastic nevi and patient anxiety.¹¹⁵ The optimal duration of follow-up remains controversial. Although most patients who are going to have recurrent disease will present in the first five years after treatment, late recurrence (more than ten years later) is well documented for melanoma.¹¹⁶ It is probably not cost effective to follow all patients intensively for metastatic disease beyond five to ten years (depending on relative risk for metastasis). However, because the lifetime risk of developing a second primary melanoma is 4-8% the panel felt that a recommendation for lifetime dermatologic surveillance for melanoma patients was justified.

It is difficult to document the effect of intensive surveillance on the outcome of patients with melanoma. A structured follow-up program could permit the earlier detection of recurrent disease at a time when it might be more amenable to potentially curative surgical resection. This follow-up would be particularly appropriate for patients at risk for regional nodal recurrence who have not undergone sentinel node biopsy, or in those patients with a positive sentinel node who elected not to undergo completion lymphadenectomy. Several other reasons for a structured follow-up program include detection of a subsequent second primary melanoma, provision of ongoing psychosocial support, identification of familial kindreds, screening for second non-melanoma primary malignancies, patient education, and documentation of the results of treatment.¹¹⁷⁻¹¹⁹

Skin cancer preventive education including sun protection measures should be promoted for patients with melanoma and their families.¹²⁰

Patients can be made aware of the various resources that discuss skin cancer prevention. Some useful resources are listed below:

- American Academy of Family Physicians. “Safe-Sun” Guidelines. American Academy of Family Physicians, 2000. (www.aafp.org/afp/20000715/375ph.html).
- Skin protection from ultraviolet light exposure: American College of Preventive Medicine Practice Policy Statement. Washington, DC: American College of Preventive Medicine. (www.acpm.org/skinprot.htm).
- Centers for Disease Control and Prevention. Preventing skin cancer: findings of the Task Force on Community Preventive Services on reducing exposure to ultraviolet light. (www.cdc.gov/mmwr/preview/mmwrhtml/rr5215a1.htm).

NCCN Recommendations

Skin examination and surveillance at least once a year for life is recommended for all melanoma patients, including those with stage 0, in-situ melanoma. Frequency of dermatologic surveillance should be determined individually, based on risk factors, including skin type, family history, presence of dysplastic nevi, and history of non-melanoma skin cancers. Clinicians should also consider educating patients about monthly self-exam of their skin and lymph nodes.

For patients with stage IA melanoma, comprehensive H&P (with specific emphasis on the regional nodes and skin) should be performed every 3-12 months for five years and annually thereafter as clinically indicated.¹²¹ For patients with stage IB-IV NED melanomas, comprehensive H&P (with emphasis on the regional nodes and skin) should be performed every 3-6 months for two years; then every 3-12 months for three years; and annually thereafter, as clinically indicated. Chest x-ray, serum LDH, and hematocrit may be performed every 6-12 months, at the discretion of the physician. These recommendations

recognize the extremely low yield of routine screening chest X-rays and screening blood tests in this population.¹²²

The consensus of the panel was that routine cross sectional imaging is not recommended for stage IB or IIA patients. In the absence of evaluable data, CT, MRI, and/or PET scans can be considered to follow-up specific signs and symptoms or to detect recurrent or metastatic disease in stage IIB or more advanced stage patients, at the discretion of the treating physician (category 2B). However, the clinical benefit of routine CT screening has not been shown, and the risks of cumulative radiation exposure from medical imaging should be considered.¹²³

Treatment of Recurrence

Initial clinical recurrence should be confirmed pathologically by FNA cytology or biopsy whenever possible.

Local Scar Recurrence

The panel recognized the distinction between true local scar recurrence after inadequate initial excision (which most likely represents locally persistent disease) and local recurrence after adequate initial excision, (which likely represents dermal lymphatic disease appearing in proximity to the wide excision scar). In the former situation, the prognosis after re-excision should be better, whereas the latter scenario is prognostically similar to recurrent regional disease.

For true local scar recurrence after inadequate primary therapy, the workup should be similar to that of the primary tumor based on lesion thickness. Re-excision to appropriate margins is recommended, with or without lymphatic mapping and sentinel node biopsy, appropriate to the microstaging of the recurrence. For a local recurrence after adequate prior wide excision, baseline imaging (chest X-ray, CT and/or PET or MRI) should be considered for staging and to evaluate specific signs or

symptoms. In the absence of extra regional disease, surgical excision with negative margin is recommended for local recurrence after initial adequate wide excision. Lymphatic mapping with sentinel node biopsy may be considered in these patients on an individual basis. After complete resection of a local recurrence following adequate primary therapy, adjuvant treatment options include clinical trial, interferon alfa (category 2B), or observation.

In-Transit Recurrence

For patients with in-transit recurrence, the workup is similar to the one previously outlined for patients presenting with in-transit disease. A surgically resectable recurrence should be re-excised with negative margins; sentinel node biopsy may be considered in these patients on an individual basis.

Unresectable recurrence could be treated with any one of the following options: intralesional injections with BCG or interferon-alfa, topical imiquimod, laser ablation therapy or hyperthermic limb perfusion or infusion. All of the local treatment options are category 2B recommendations. Alternatively, patients can be treated in the context of a clinical trial or with systemic therapy. In unusual circumstances, radiation therapy may be effective in achieving regional control (category 2B).

After complete response to any of these modalities, options for adjuvant treatment include a clinical trial, high-dose interferon alfa (category 2B), or observation.

Regional Nodal Recurrence

For patients presenting with regional nodal recurrence, the clinical diagnosis should be confirmed preferably by FNA biopsy. Workup of these patients includes FNA (preferred) or lymph node biopsy, chest x-ray and/or chest CT, LDH, pelvic CT if the inguinofemoral nodes are

clinically positive, and abdominal/pelvic CT, MRI of the brain, and PET scan as indicated.

For patients who have not undergone prior lymph node dissection, a complete lymph node dissection is appropriate. For patients who have had an incomplete prior lymph node dissection, complete lymph node dissection is recommended. If the patient underwent a previous “complete” lymph node dissection, excision of the recurrence to negative margins is recommended. Postoperative adjuvant RT may decrease the likelihood of further regional nodal recurrences and can be considered in selected patients with completely resected nodal recurrence, with risk factors such as multiple involved nodes or extranodal disease, especially in the head and neck region (category 2B).

Distant Recurrence

For patients presenting with distant recurrence, the workup and treatment options are similar to those outlined previously for patients presenting initially with stage IV metastatic disease.

Summary

The NCCN Melanoma Guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than the recommendations for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for the melanoma patient, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by the clinician’s judgment and other factors, such as local resources and expertise as well as the individual patient’s needs, wishes, and expectations. Furthermore, the NCCN

Melanoma Guidelines undergo annual revision and are continually revised as new data become available.



Discussion
update in
progress

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin*. 2008;58:71-96.
2. Surveillance Epidemiology and End Results. <http://seer.cancer.gov/statfacts/html/melan.html#ref11>
National Cancer Institute. 2008.
3. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. *N Engl J Med*. 2003;349:2233-2240.
4. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. *Cancer*. 1989;63:386-389.
5. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. *Dermatol Surg*. 2006;32:481-492.
6. Jensen EH, Kim A, Margolin KA, Vernon K, Sondak VK. Melanoma and other skin cancers. *Cancer Management: A Multidisciplinary Approach* 9th ed. 2005:531-562.
7. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. *N Engl J Med*. 2004;351:998-1012.
8. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol*. 2001;19:3635-3648.
9. Greene FL, Page DL, Fleming ID. *AJCC Cancer Staging Manual* 6th ed. New York Springer-Verlag. 2002.
10. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol*. 2001;19:3622-3634.
11. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. *J Cutan Pathol*. 2005;32:268-273.
12. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. *Cancer*. 2003;97:1488-1498.
13. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. *Ann Surg Oncol*. 2004;11:426-433.
14. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. *J Clin Oncol*. 2007;25:1129-1134.
15. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. *Cancer*. 2007;109:100-108.
16. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. *Ann Surg Oncol*. 2004;11:247-258.
17. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. *J Am Acad Dermatol*. 2001;45:579-586.
18. Neuman HB, Patel A, Ishill N, et al. A single-institution validation of the AJCC staging system for stage IV melanoma. *Ann Surg Oncol*. 2008;15:2034-2041.
19. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. *Ann Surg Oncol*. 2000;7:469-474.
20. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. *J Clin Oncol*. 1993;11:638-643.
21. Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL. Evaluation of staging chest radiographs and serum lactate

dehydrogenase for localized melanoma. *J Am Acad Dermatol.* 2004;51:399-405.

22. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. *Cancer.* 2007;110:1107-1114.

23. Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. *J Clin Oncol.* 2006;24:2858-2865.

24. Gold JS, Jaques DP, Busam KJ, Brady MS, Coit DG. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. *Ann Surg Oncol.* 2007;14:2133-2140.

25. Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. *Arch Surg.* 2004;139:831-836; discussion 836-837.

26. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. *J Clin Oncol.* 1995;13:2104-2108.

27. Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. *Ann Surg Oncol.* 1997;4:396-402.

28. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. *Ann Surg Oncol.* 1997;4:252-258.

29. Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. *Arch Surg.* 2006;141:284-288.

30. Maubec E, Lumbroso J, Masson F, et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of

patients with a primary melanoma thicker than 4 mm. *Melanoma Res.* 2007;17:147-154.

31. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. *Cancer.* 2005;104:570-579.

32. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)f] fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. *Ann Surg Oncol.* 2006;13:525-532.

33. National Institutes of Health. After treatment of early melanoma, should patients and family members be followed? Why and How? NIH Consensus Statement. 1992;10:1-26.

34. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Arch Surg.* 1991;126:438-441.

35. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. *N Engl J Med.* 1988;318:1159-1162.

36. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. *Ann Surg Oncol.* 2001;8:101-108.

37. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. *Ann Surg.* 1993;218:262-267; discussion 267-269.

38. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. *Cancer.* 2000;89:1495-1501.

39. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer*. 2003;97:1941-1946.
40. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. *N Engl J Med*. 2004;350:757-766.
41. Haigh PI, DiFronzo LA, McCreedy DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. *Can J Surg*. 2003;46:419-426.
42. Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure. *J Am Acad Dermatol*. 1997;37:758-764.
43. Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. *J Am Acad Dermatol*. 1997;37:236-245.
44. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. *Dermatol Surg*. 2008;34:147-151.
45. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. *Br J Dermatol*. 2003;149 Suppl 66:66-70.
46. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. *Clin Exp Dermatol*. 2004;29:15-21.
47. Spenny ML, Walford J, Werchniak AE, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. *Cutis*. 2007;79:149-152.
48. Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. *J Am Acad Dermatol*. 2006;54:19-27.
49. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. *Ann Surg*. 2005;242:302-311; discussion 311-303.
50. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. *N Engl J Med*. 2006;355:1307-1317.
51. Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications. *Surg Oncol Clin N Am*. 2007;16:35-54.
52. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. *Arch Surg*. 2008;143:892-899; discussion 899-900.
53. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. *J Clin Oncol*. 2003;21:1326-1331.
54. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ, 3rd. The prognostic importance of sentinel lymph node biopsy in thin melanoma. *Ann Surg Oncol*. 2006;13:927-932.
55. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. *Ann Surg Oncol*. 2006;13:302-309.
56. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. *Ann Surg Oncol*. 2002;9:637-645.
57. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. *Ann Surg Oncol*. 2000;7:160-165.
58. Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. *J Dtsch Dermatol Ges*. 2008;6:198-203.

59. Edwards MJ, Martin KD, McMasters KM. Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. *Surg Oncol.* 1998;7:51-57.
60. Glass FL, Cottam JA, Reintgen DS, Fenske NA. Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. *J Am Acad Dermatol.* 1998;39:603-610.
61. Kang JC, Wanek LA, Essner R, Faries MB, Foshag LJ, Morton DL. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. *J Clin Oncol.* 2005;23:4764-4770.
62. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. *Ann Surg.* 1999;230:453-463; discussion 463-455.
63. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? *Am J Dermatopathol.* 2003;25:371-376.
64. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. *Ann Surg Oncol.* 2008;15:316-322.
65. Coit DG. Extent of groin dissection for melanoma. *Surg Clin North Am.* 1992;1:271-280.
66. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. *Arch Surg.* 1989;124:162-166.
67. Shen P, Conforti AM, Essner R, Cochran AJ, Turner RR, Morton DL. Is the node of Cloquet the sentinel node for the iliac/obturator node group? *Cancer J.* 2000;6:93-97.
68. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. *J Clin Oncol.* 2006;24:4464-4471.
69. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. *J Clin Oncol.* 2004;22:3677-3684.
70. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. *Lancet.* 2001;358:866-869.
71. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. *Lancet.* 1998;351:1905-1910.
72. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. *J Clin Oncol.* 1998;16:1425-1429.
73. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. *J Clin Oncol.* 2004;22:53-61.
74. Eggermont AM, Suci S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. *Lancet.* 2005;366:1189-1196.
75. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol.* 1996;14:7-17.

76. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. *J Clin Oncol*. 2000;18:2444-2458.
77. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. *J Clin Oncol*. 2001;19:2370-2380.
78. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. *N Engl J Med*. 2006;354:709-718.
79. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. *J Clin Oncol*. 2002;20:1818-1825.
80. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. *Clin Cancer Res*. 2004;10:1670-1677.
81. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. *Cancer*. 2006;106:1431-1442.
82. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. *Cancer Control*. 2002;9:16-21.
83. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. *Cancer*. 2008;112:982-994.
84. Hurley KE, Chapman PB. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. *Oncologist*. 2005;10:739-742.
85. Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. *Cancer*. 2004;100:383-389.
86. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. *Ann Surg Oncol*. 1995;2:445-449.
87. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. *Curr Treat Options Oncol*. 2005;6:185-193.
88. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. *Lancet Oncol*. 2003;4:748-759.
89. Houghton AN, Coit DG, Daud A, et al. Melanoma. *J Natl Compr Canc Netw*. 2006;4:666-684.
90. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. *J Exp Clin Cancer Res*. 2000;19:21-34.
91. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol*. 2000;18:158-166.
92. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. *Cancer*. 1989;64:2024-2029.
93. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. *Cancer Treat Rep*. 1987;71:465-469.
94. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol*. 1999;17:2745-2751.

95. Agarwala SS, Keilholz U, Hogg D. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (Abstract). *J Clin Oncol*. 2007;25 (18 Supp):8510.
96. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. *Cancer*. 2006;106:375-382.
97. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol*. 1999;17:2105-2116.
98. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res*. 2008;14:5610-5618.
99. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. *Ann Oncol*. 1996;7:827-835.
100. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. *J Clin Oncol*. 1998;16:1752-1759.
101. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. *J Clin Oncol*. 2002;20:2045-2052.
102. Atkins MB, Hsu J, Lee S, et al. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol*. 2008.
103. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. *Ann Oncol*. 2006;17:571-577.
104. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. *J Clin Oncol*. 2005;23:6747-6755.
105. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. *J Clin Oncol*. 2002;20:1600-1607.
106. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. *J Clin Oncol*. 2007;25:5426-5434.
107. Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? *Ann Surg*. 2003;238:743-747.
108. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. *J Dermatol Surg Oncol*. 1993;19:985-990.
109. Wolf IH, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. *Dermatol Surg*. 2004;30:244-247.
110. Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. *J Surg Oncol*. 2004;88:1-3.
111. Fraker DL, Coit DG. Isolated perfusion of extremity tumors. Regional therapy of advanced cancer. 1997:333-350.

112. Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. *Lancet Oncol.* 2003;4:359-364.

113. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. *Ann Surg Oncol.* 2002;9:127-136.

114. Allen PJ, Coit DG. The surgical management of metastatic melanoma. *Ann Surg Oncol.* 2002;9:762-770.

115. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. *JAMA.* 2005;294:1647-1654.

116. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. *Ann Surg.* 1990;212:173-177.

117. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. *Arch Gen Psychiatry.* 1993;50:681-689.

118. Gutman M, Cnaan A, Inbar M, et al. Are malignant melanoma patients at higher risk for a second cancer? *Cancer.* 1991;68:660-665.

119. Kang S, Barnhill RL, Mihm MC, Jr., Sober AJ. Multiple primary cutaneous melanomas. *Cancer.* 1992;70:1911-1916.

120. Rhodes AR. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? *Cancer.* 1995;75:613-636.

121. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. *Dermatology.* 1995;191:199-203.

122. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. *JAMA.* 1995;274:1703-1705.

123. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med.* 2007;357:2277-2284.

Discussion
update in
progress